Investigators at the National Cancer
Institute (NCI), Bethesda, Maryland, conducted the preclinical study in
collaboration with Chemokine Therapeutics.
The NCI, established under the National Cancer Act of 1937, is the principal
agency for cancer research and training of the United States federal
government.chemokine.
Strategic Growth International
212-838-1444
jzimmons@sgi-ir. Food and Drug Administration (FDA) is
currently reviewing Abbott's New Drug Application (NDA) for Xinlay submitted
on Dec.

" [Poster Session, Poster D17, Abstract#4603:
Saturday, May 14, 8:00 a.m.

infancy sarcoma

In addition, Chemokine maintains
a drug discovery program to identify new chemokine-based drug candidates. Without limiting the
foregoing, the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects ", "projects", and similar expressions are intended to
identify forward-looking statements.net

U.D.

About INEX

INEX is a Canadian biopharmaceutical company developing and
commercializing proprietary drugs and drug delivery systems to improve the
treatment of cancer ., Level 2, Hall
F3, 230A]
-- "Quality of Life as a Potential Predictor For Morbidity and Mortality
in Patients with Metastatic Hormone-Refractory Prostate Cancer.m., Level 2,
Hall F3]

About Xinlay(TM)
Xinlay is an investigational, oral, once-daily , non-hormonal, non-
chemotherapy, agent that belongs to a class of compounds known as selective
endothelin -A receptor antagonists (SERA(TM)). These tissues include
muscles, tendons, fat, blood vessels, nerves and tissues around joints.
Abbott currently markets tests for detection of cancer, including a PSA
test. The
company employs more than 60,000 people and markets its products in more than
130 countries.

esthesioneuroblastom oncologists

The NCI is a component of the National
Institutes of Health (NIH), one of eight agencies that compose the Public
Health Service (PHS) in the Department of Health and Human Services (DHHS). have signed strategic agreements with Chemokine to
collaborate on research and development . Anderson Cancer Center in Houston, Texas and a pivotal phase 2b
multi-center clinical trial. Two -thirds of patients were resistant to their last therapy. Such factors include, among
others, INEX 's stage of development, lack of product revenues, additional
capital requirements, risks associated with the completion of clinical trials
and obtaining regulatory approval to market INEX's products , the ability to
protect its intellectual property and dependence on collaborative partners." [Poster Session, Poster
8, Abstract #8527: Monday, May 16, 8:00 a. ABT-510
currently is being studied in Phase II clinical trials in various cancers
including sarcoma, lymphoma, and kidney cancer .

neuroblastoma cancerbacup

Background on how Cancers Spread and the Potential Role of CTCE-9908

Recently , researchers discovered that the growth and spread of cancer
are affected by a chemokine known as stromal cell-derived factor 1 (SDF-1). The investigator concluded that this
study supports further investigation of Marqibo in this disease.

Pediatric malignancies

On May 14, 2005 , clinical investigators from the M. Such
forward-looking statements involve known and unknown risks , uncertainties and
other factors that may cause the actual results, events or developments to be
materially different from any future results, events or developments expressed
or implied by such forward-looking statements., Level 2, Hall C]

ABT-510
-- "A Randomized Phase II Study of the Thrombospondin-Mimetic Peptide ABT-
510 in Patients with Advanced Soft Tissue Sarcoma .

Childhood cancer arises from the primitive cells, thus the types of cancer found in children is significantly different than cancer in adults.

myelogenous medulloblastoma

net

Safe Harbor Statement under the U."
The following are summaries of two posters presented at the Annual
Meeting of the American Society of Clinical Oncology (ASCO) being held
May 13-17, 2005 and one poster presented at the American Society of Pediatric
Hematology/Oncology (ASHPO) Annual Meeting being held May 14-16, 2005 in
Washington, DC." [Oral
Presentation, Abstract #9013: Saturday, May 14, 1:45 p.

About ABT-751
An investigational oral, once-daily antimitotic (a class of drugs that
inhibit cell division), ABT-751 is currently being studied in Phase II
clinical trials for use in lung, colon, breast and kidney cancers.

osteosarcoma arises

Zimmons, Ph.com
Fax: (416) 815-0080

The data were reported on 29 patients with a median age of 34 and a
median of four prior chemotherapy treatments.inexpharm., Several data
presentations from Abbott's portfolio of investigational cancer treatments
will be presented this week at the American Society of Clinical Oncology
(ASCO) annual meeting taking place in Orlando.

neuroblastoma rhabdomyosarcoma

For further information, contact:
Ian Harper,
Chemokine Therapeutics Corp.

Data to be presented on
these investigational agents includes:

Xinlay
-- "Meta -Analysis of Clinical Trials of Atrasentan 10 mg in Metastatic
Hormone-Refractory Prostate Cancer.
Trials are ongoing in men with hormone-refractory prostate cancer that has
not spread (non-metastatic), as well as in hormone-naive men (prostate cancer
patients who have not received hormone therapy) with rising prostate-specific
antigen (PSA) following prostate cancer surgery. A Phase II
trial is planned for refractory pediatric neuroblastoma. ABT-751 was granted
Orphan drug designation by the FDA for pediatric neuroblastoma. These approaches address multiple phases of cancer
progression, including signal transduction, angiogenesis (new blood vessel
formation) and programmed cell death (apoptosis). Economic, competitive, governmental, technological and other
factors that may affect Abbott's operations are discussed in Exhibit 99.

medulloblastoma tumor

Chemokine has two product candidates in clinical
trials; CTCE-0214, for immune system recovery, and CTCE-9908, to prevent the
spread of cancer and its continued growth.238)
E-mail: rmarshall@equicomgroup.
The data was from a phase 2 clinical study of Marqibo as a single-agent
treatment in pediatric patients who had relapsed after receiving standard
therapy.com
Website: http://www. In
sarcomas that have spread , the five-year survival rate is between 10 and 15
percent, highlighting the compelling need to find therapies that will help
prolong survival in these patients. We
caution that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated.

oncologists myelogenous

-NCI Sponsored Preclinical Study to Report on Anti-Metastatic
Activity on April 17th, 2005-

VANCOUVER, Feb. 17 - Chemokine Therapeutics Corp.aacr. For more information, please visit
our website at http://www.S. Further information about INEX and Marqibo can be found
at http://www."
[Poster Session, Poster N13, Abstract #8095: Sunday, May 15, 2:00 p.

Childhood cancer is rare.

infancy arises

SDF-1 is produced naturally in organs such as the bone marrow, liver, and
lungs and is an important regulator of stem cells. A recently completed Phase I study of this compound
in healthy adults did not reveal any significant toxicity.

Chemokine 's Research Collaboration with the NCI, Bethesda, Maryland

Chemokine has been collaborating with the National Cancer Institute's
Pediatric Oncology Branch since February, 2004. Cooper/Jennifer K.

About Abbott
Abbott is committed to the discovery and development of innovative
treatments to help patients in the fight against cancer.

The team specialists include pediatric oncologists , surgeons, radiation oncologists, pediatric oncology nurses and nurse practitioners.

medulloblastoma neuroblastoma

The time to progression was
approximately four months and overall median survival was approximately
8. - 5:00 p.m.m. ABT-751 is
not a multi-drug resistant (MDR) substrate.1 of
our Quarterly Report on Securities and Exchange Commission Form 10-Q for the
quarter ended June 30, 2004, and are incorporated by reference .

cancerbacup cancers

Chemokine to Present Anti-Cancer Compound at the American Association for Cancer Research

SDF-1 acts on two important
receptors, CXCR4 and CXCR7, which are expressed in both healthy stem cells and
various common cancers. VANCOUVER, May 17 - Inex Pharmaceuticals
Corporation ("INEX"; TSX: IEX) announced today results from clinical studies
indicating its lead anticancer drug, Marqibo (TM), has shown anti-tumor
activity in patients with relapsed non-Hodgkin's lymphoma (NHL), Hodgkin 's
disease and pediatric malignancies.
A total of 211 patients were treated in the combined trials. The median
age of the patients was 62 and the median number of prior treatment regimens
was three.
The investigator presenting the combined data concluded that the
single-agent treatment of Marqibo in this heavily pre-treated population
demonstrated a clinically meaningful rate of response for patients with
multiply relapsed aggressive NHL.

Hodgkin's disease

On May 17, 2005 follow-up data was presented at ASCO for a phase 2 study
conducted at M.D. The investigator concluded that Marqibo warrants further
study in combination regimens to treat pediatric cancers .,
Level 4, Valencia Room 415B]

ABT-751
-- "Preliminary Results of a Phase II Study of ABT-751 in Subjects with
Taxane-Refractory Non-small Cell Lung Carcinoma.

arises infancy

Pharmaceutical Product Development, Inc.

INEX Presents Marqibo(TM) Clinical Data at Medical Meetings

ABBOTT PARK , Ill. The
FDA's Oncologic Drugs Advisory Committee will review Xinlay at its September
2005 meeting .
- 6:00 p.m.
Abbott is a global, broad-based health care company devoted to the
discovery , development, manufacture and marketing of pharmaceuticals and
medical products, including nutritionals , devices and diagnostics.

And, because children are still growing they often have special physical and emotional needs.

gliomas retinoblastoma

Chemokine designed
CTCE-9908 to inhibit the growth and spread of certain common cancers with the
potential for use with existing therapies (chemotherapy, surgery, and
radiation ) to improve treatment outcomes. (Toronto Stock Exchange: CTI)

Chemokine is a biotechnology company developing drugs in the field of
chemokines and cytokines, a family of small, soluble proteins , primarily
located within the bone marrow to regulate stem cell growth, differentiation
and maturation .com

The U.S." [Poster Discussion, Poster 19,
Abstract #4563: Sunday, May 15, 1:00 p." [Poster Session,
Poster L15, Abstract#7137: Tuesday, May 17, 8:00 a.m., Level 2, Hall C]
-- "Phase I Trial of Oral ABT-751 in Pediatric Patients: Preliminary
Evidence of Activity in Neuroblastoma (NBL).

Childhood cancer typically refers to the type of cancer that affects the age groups from infancy to twenty one years old.

hematologic wilm

(PPDI) and Procter + Gamble
Pharmaceuticals , Inc.
Phone: 604-739-7500
Email: kcook@hoggan. to 2:00 p.

hematologic myelogenous

Forward Looking Statements

There are forward-looking statements contained herein that are not based
on historical fact, including without limitation statements containing the
words "believes," "may," "plans," "will ," "estimate," "continue,"
"anticipates," "intends," "expects," and similar expressions.m. - 12:00 p.

Private Securities Litigation Reform Act of 1995 -
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward -looking statements for
the purposes of the Private Securities Litigation Reform Act of 1995.

cancers lymphoma

chemokine . Securities and
Exchange Commission and Canadian securities regulatory authorities. Twenty-eight patients were
evaluable for response with an overall response rate of 36% (ten patients).
These factors should be considered carefully and readers are cautioned not to
place undue reliance on such forward-looking statements.

Abbott to Present New Data on Its Oncology Pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting

Abbott also markets nutritional products designed to meet the
unique dietary needs of cancer patients.

Children are often treated at specialized Centers by team specialists who know the difference between childhood and adult cancers.

oncologists infancy

You are cautioned that such statements
are subject to a multitude of risks and uncertainties that could cause actual
results , future circumstances, or events to differ materially from those
projected in the forward-looking statements.
Director of Investor Relations + Corporate Development
Phone: (604) 822-0305
E-mail: iharper@chemokine.
David Main, President and CEO of INEX said, "The data presented from
these clinical studies continue to demonstrate the activity of Marqibo in a
variety of different cancers.

Relapsed non-Hodgkin's lymphoma

Combined results from two different clinical trials were presented at
ASCO in Orlando, Florida on May 17, 2005.
The overall response rate was 28% (59 patients), of which 7%
(15 patients) had complete responses. The Company disclaims
any obligation to update any such factors or to publicly announce the result
of any revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments .
Mimicking the behavior of a natural anti-angiogenic protein, thrombospondin-1
(TSP-1), ABT-510 is being evaluated to determine its potential to block
multiple pro-angiogenic growth factors including VEGF, bFGF and IL-8. Abbott's innovative genomic tests include Vysis(R) UroVysion(TM), for
monitoring the recurrence of bladder cancer, and PathVysion(R), for detecting
the HER-2 gene, which predicts potential treatment benefit in women with
breast cancer.com .

rhabdoid retinoblastoma

For this purpose, any
statements that are contained herein that are not statements of historical
fact may be deemed to be forward -looking statements.D. The trial was designed to determine the response rate, the
progression-free survival rate, and the safety of Marqibo in pediatric
patients.

Contacts Information
Investors
Ian Mortimer
Vice President, Finance and Chief Financial Officer
Phone: 604-419-3200
Email: info@inexpharm. - 12:00 p. The
company has several different classes of compounds in various stages of
clinical development.

However, it is possible for young adults to also develop a 'childhood cancer'.

neuroblastoma carcinoma

These risks include, but are not
limited to, those associated with the success of research and development
programs, the regulatory approval process, competition , securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, financing capability, the
potential dilutive effects of any financing, reliance on subcontractors and
key personnel and other risks detailed from time-to-time in the Company 's
public disclosure documents and other filings with the U. Both trials evaluated Marqibo as a single -agent
treatment for patients with relapsed aggressive NHL. Anderson Cancer
Center presented a poster at the ASHPO Annual Meeting in Washington, DC.
Abbott also will present Phase II results of its investigational
angiogenesis inhibitor, ABT-510 in soft tissue sarcoma, and an oral
investigational chemotherapy agent, ABT-751, in lung and renal cell (kidney)
carcinomas and Phase I results in neuroblastoma .m. SERAs antagonize the effect of
endothelin-1 (ET-1), one of the proteins thought to be involved in the
stimulation of the spread of cancer.

Childhood cancers tend to be more aggressive than adult cancers.

gliomas esthesioneuroblastom

The AACR will make the results of the study available in mid-March
through the AACR website at http://www.
CTCE-9908 is an analog and antagonist of SDF-1 developed by scientists at
Chemokine using rational-based drug design. CTCE-9908 binds competitively to
the CXCR4/CXCR7 receptors on cancer cells which prevents the interaction of
SDF-1 with the receptors. The NCI continues to evaluate
the oncological potential of CTCE-9908.com

Canadian Media Enquiries
------------------------
Ross Marshall
The Equicom Group Inc.
These combined results are from a phase 2a clinical trial conducted at
M.5 months.
The therapy was well tolerated , with mostly mild to moderate toxicities,
despite the number of prior therapies.

lymphoma esthesioneuroblastom

Chemokine will announce
additional information at the poster session on Sunday, April 17, 2005. The presence of CXCR4 and CXCR7 on cancer cells allows
these cells to migrate from the original cancer site to new sites that are
rich in SDF-1, such as bone marrow, liver, and lungs, where they develop new
blood vessels (angiogenesis) and form new tumors (metastases). Private Securities Litigation
Reform Act of 1995: Statements in this document regarding managements' future
expectations, beliefs, goals, plans or prospects constitute forward-looking
statements that involve risks and uncertainties, which may cause actual
results to differ materially from the statements made.net
Internet: http://www. Anderson Cancer Center of Marqibo as a single-agent
treatment for patients with relapsed or refractory Hodgkin 's disease.
The data from this trial in 30 patients with a variety of pediatric
malignancies indicate that the drug was well tolerated with side effects being
mild to moderate in severity and that Marqibo can be used for prolonged
periods of time. Marqibo showed promising activity in pretreated patients with
soft tissue sarcomas.com.inexpharm.
Abbott (NYSE: ABT) will present Phase III data regarding Xinlay(TM)
(atrasentan) at ASCO.,
Level 2, Hall C]
-- "Preliminary Phase II Results of ABT-751 in Subjects with Advanced
Renal Cell Carcinoma. MDR substrate compounds often
develop resistance to chemotherapy drugs, and ABT-751 is active pre-clinically
in chemo-resistant tumors.
Abbott's news release and other information are available on the company 's
Web site at http://www.

osteosarcoma esthesioneuroblastom

(Chemokine) (Toronto Stock Exchange: CTI), a biotechnology company developing
drugs in the field of chemokines and cytokines, today announced that the
American Association for Cancer Research (AACR) has accepted Chemokine
Therapeutic's lead product candidate CTCE-9908 for presentation in a Poster
Session at the 2005 Annual Meeting in Anaheim, California. Forward-
looking statements are made as of the date hereof, and the Company disclaims
any intention and has no obligation or responsibility, except as required by
law, to update or revise any forward-looking statements, whether as a result
of new information, future events, or otherwise. Media Enquiries
--------------------
Richard E. Our current focus for Marqibo is finalizing the
design of phase 3 clinical trials in non-Hodgkin's lymphoma and acute
lymphoblastic leukemia in order to file Special Protocol Assessments with the
United States Food and Drug Administration as well as continue our discussions
with potential development and commercialization partners.

About Marqibo(TM)

Marqibo (sphingosomal vincristine) is a proprietary drug comprised of the
widely used off-patent anticancer drug vincristine encapsulated in INEX's
sphingosomal drug delivery technology .m. - 12:00 p.m.
ABT-510 was granted an Orphan Drug designation by the FDA for soft tissue
sarcoma , a malignant tumor that can develop in tissues that connect, support
or surround other structures and organs of the body. Abbott's oncology
research is focused on developing targeted therapies with low toxicity. For further information about atrasentan
(Xinlay(TM)), call (800) 633-9110.

hematologic genitourinary

About Chemokine Therapeutics Corp. S.D.

medulloblastoma lymphoma

org. Chemokines and cytokines also play an important role in cancer
and autoimmune disorders which can paradoxically contribute to the survival
and growth of such diseases.S.
Phone: (416) 815-0700 (Ext. This technology is designed to provide
prolonged blood circulation, tumor accumulation and extended drug release at
the cancer site. These characteristics are intended to increase the
effectiveness while reducing the side effects of the encapsulated drug .com

Media
Karen Cook Boas
James Hoggan + Associates Inc. 14, 2004, for the treatment of metastatic hormone-refractory prostate
cancer, an advanced stage of the disease that no longer responds to hormone
treatment and has spread to other parts of the body, such as the bone .m.m. Additionally, Xinlay is
being evaluated in combination trials with approved treatments for advanced
prostate cancer. Abbott continues to explore Xinlay in other cancers,
including kidney , ovarian, brain and non-small cell lung cancers.

About ABT-510
ABT-510 is an investigational angiogenesis inhibitor, that belongs to a
class of drugs that works by cutting off the blood supply that feeds tumors.abbott. We undertake
no obligation to release publicly any revisions to forward -looking statements
as the result of subsequent events or developments.